We use cookies to understand how you use our site and to improve your experience.
This includes personalizing content and advertising.
By pressing "Accept All" or closing out of this banner, you consent to the use of all cookies and similar technologies and the sharing of information they collect with third parties.
You can reject marketing cookies by pressing "Deny Optional," but we still use essential, performance, and functional cookies.
In addition, whether you "Accept All," Deny Optional," click the X or otherwise continue to use the site, you accept our Privacy Policy and Terms of Service, revised from time to time.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
LH Expands Genetic Testing in CRC Through New Collab: Stock to Gain?
Read MoreHide Full Article
Key Takeaways
Labcorp teamed with Alliance for Clinical Trials in Oncology on a national colorectal cancer trial.
Labcorp will provide exclusive Invitae genetic testing for patients and at-risk relatives.
The NCI-sponsored study will assess outreach and multigene testing impacts on CRC care.
Labcorp (LH - Free Report) recently teamed up with the Alliance for Clinical Trials in Oncology to advance a national, multicenter clinical trial for patients newly diagnosed with colorectal cancer (“CRC”). This collaboration reflects Labcorp's continued commitment to advancing genetics-based approaches to improve outcomes for patients with cancer, while supporting high-impact clinical research in collaboration with leading research organizations.
Predicting LH Stock Movement Following the News
Following the announcement, Labcorp’s shares edged down 0.7%, finishing at $260.06 last Friday.
In recent years, Labcorp has built a significant number of strategic relationships with health systems and regional/local laboratories, expanding the patient and provider network, and strengthening its presence in key markets. In the first quarter of 2026, enterprise revenues grew 5.8% year over year, with net acquisitions contributing 1.4%. We expect this latest development to drive positive market sentiment toward LH stock in the coming days.
Labcorp has a market capitalization of $21.32 billion. The company’s earnings yield of 5.9% compares favorably with the industry’s 4% yield. In the trailing four quarters, it delivered an average earnings surprise of 2.52%.
Significance of LH’s Collab for Multi-Institution Trial
According to various sources, inherited genetic variants contribute to approximately 10% of all colorectal cancer cases. Testing family members of individuals with an inherited cancer-associated variant, called cascade testing, is a well-established approach to cancer prevention, particularly for Lynch syndrome, the most common hereditary colorectal cancer syndrome.
The trial will evaluate approaches to increase germline genetic testing among at-risk family members, as well as the impact of multigene panel testing on care for newly diagnosed patients. Leveraging its Invitae testing, Labcorp will serve as the exclusive genetic testing provider, supporting participating sites with its national scale and scientific expertise.
The trial will assess proactive outreach by healthcare providers which will improve participation of first-degree relatives in cascade genetic testing. In parallel, the trial will assess the impact of multigene panel testing on care for patients newly diagnosed with colorectal cancer.
About the Multi-Center CRC Genetic Testing Trial
The trial is sponsored by the National Cancer Institute (“NCI”) and led and conducted by the Alliance for Clinical Trials in Oncology. It includes participation from the NCI National Clinical Trials Network, which comprises academic medical centers, community oncology health systems and NCI-designated cancer centers. The study is expected to enroll patients and their relatives nationwide, including sites in Puerto Rico.
Industry Prospects Favor LH
Per the Grand View Research report, the global hereditary cancer testing market size is projected to reach $14.45 billion by 2033, growing at a CAGR of 13.76% from 2025 to 2033. The demand for hereditary cancer testing is increasing due to technological advancements in genetic testing for cancer detection, integration with precision medicine and growing awareness through public and government initiatives.
Image Source: Zacks Investment Research
Another Recent Development By LH
In the previous week, Labcorp announced the availability of its expanded DPYD Genotyping test to help identify cancer patients who may be at increased risk for severe or life-threatening side effects from fluoropyrimidine chemotherapy.
LH Stock Price Performance
In the past year, LH’s shares have risen 5.4% compared with the industry’s 1% growth.
LH’s Zacks Rank and Key Picks
Labcorp currently carries a Zacks Rank #3 (Hold).
Some better-ranked stocks in the broader medical space are Globus Medical (GMED - Free Report) , Integra LifeSciences (IART - Free Report) and Phibro Animal Health (PAHC - Free Report) .
Globus Medical has an earnings yield of 5.5%, well ahead of the industry’s negative 3% yield. Its earnings surpassed estimates in each of the trailing four quarters, the average surprise being 26.3%. The company’s shares have rallied 43.8% against the industry’s 4.8% decline over the past year.
Integra LifeSciences, carrying a Zacks Rank #2 (Buy) at present, has an earnings yield of 16% against the industry’s negative 3% yield. Shares of the company have gained 22.8% compared with the industry’s 4.8% growth. IART’s earnings topped estimates in each of the trailing four quarters, the average surprise being 16.8%.
Phibro Animal Health, carrying a Zacks Rank #2 at present, has an earnings yield of 9.2% compared with the industry’s 2.8% yield. Shares of the company have climbed 43.1% against the industry’s 27.9% decline. PAHC’s earnings beat estimates in each of the trailing four quarters, the average surprise being 16.3%.
Zacks' 7 Best Strong Buy Stocks (New Research Report)
Valued at $99, click below to receive our just-released report
predicting the 7 stocks that will soar highest in the coming month.
View the Zacks #1 Rank List
Image: Bigstock
LH Expands Genetic Testing in CRC Through New Collab: Stock to Gain?
Key Takeaways
Labcorp (LH - Free Report) recently teamed up with the Alliance for Clinical Trials in Oncology to advance a national, multicenter clinical trial for patients newly diagnosed with colorectal cancer (“CRC”). This collaboration reflects Labcorp's continued commitment to advancing genetics-based approaches to improve outcomes for patients with cancer, while supporting high-impact clinical research in collaboration with leading research organizations.
Predicting LH Stock Movement Following the News
Following the announcement, Labcorp’s shares edged down 0.7%, finishing at $260.06 last Friday.
In recent years, Labcorp has built a significant number of strategic relationships with health systems and regional/local laboratories, expanding the patient and provider network, and strengthening its presence in key markets. In the first quarter of 2026, enterprise revenues grew 5.8% year over year, with net acquisitions contributing 1.4%. We expect this latest development to drive positive market sentiment toward LH stock in the coming days.
Labcorp has a market capitalization of $21.32 billion. The company’s earnings yield of 5.9% compares favorably with the industry’s 4% yield. In the trailing four quarters, it delivered an average earnings surprise of 2.52%.
Significance of LH’s Collab for Multi-Institution Trial
According to various sources, inherited genetic variants contribute to approximately 10% of all colorectal cancer cases. Testing family members of individuals with an inherited cancer-associated variant, called cascade testing, is a well-established approach to cancer prevention, particularly for Lynch syndrome, the most common hereditary colorectal cancer syndrome.
The trial will evaluate approaches to increase germline genetic testing among at-risk family members, as well as the impact of multigene panel testing on care for newly diagnosed patients. Leveraging its Invitae testing, Labcorp will serve as the exclusive genetic testing provider, supporting participating sites with its national scale and scientific expertise.
The trial will assess proactive outreach by healthcare providers which will improve participation of first-degree relatives in cascade genetic testing. In parallel, the trial will assess the impact of multigene panel testing on care for patients newly diagnosed with colorectal cancer.
About the Multi-Center CRC Genetic Testing Trial
The trial is sponsored by the National Cancer Institute (“NCI”) and led and conducted by the Alliance for Clinical Trials in Oncology. It includes participation from the NCI National Clinical Trials Network, which comprises academic medical centers, community oncology health systems and NCI-designated cancer centers. The study is expected to enroll patients and their relatives nationwide, including sites in Puerto Rico.
Industry Prospects Favor LH
Per the Grand View Research report, the global hereditary cancer testing market size is projected to reach $14.45 billion by 2033, growing at a CAGR of 13.76% from 2025 to 2033. The demand for hereditary cancer testing is increasing due to technological advancements in genetic testing for cancer detection, integration with precision medicine and growing awareness through public and government initiatives.
Image Source: Zacks Investment Research
Another Recent Development By LH
In the previous week, Labcorp announced the availability of its expanded DPYD Genotyping test to help identify cancer patients who may be at increased risk for severe or life-threatening side effects from fluoropyrimidine chemotherapy.
LH Stock Price Performance
In the past year, LH’s shares have risen 5.4% compared with the industry’s 1% growth.
LH’s Zacks Rank and Key Picks
Labcorp currently carries a Zacks Rank #3 (Hold).
Some better-ranked stocks in the broader medical space are Globus Medical (GMED - Free Report) , Integra LifeSciences (IART - Free Report) and Phibro Animal Health (PAHC - Free Report) .
Globus Medical has an earnings yield of 5.5%, well ahead of the industry’s negative 3% yield. Its earnings surpassed estimates in each of the trailing four quarters, the average surprise being 26.3%. The company’s shares have rallied 43.8% against the industry’s 4.8% decline over the past year.
GMED sports a Zacks Rank #1 (Strong Buy) at present. You can see the complete list of today’s Zacks #1 Rank stocks here.
Integra LifeSciences, carrying a Zacks Rank #2 (Buy) at present, has an earnings yield of 16% against the industry’s negative 3% yield. Shares of the company have gained 22.8% compared with the industry’s 4.8% growth. IART’s earnings topped estimates in each of the trailing four quarters, the average surprise being 16.8%.
Phibro Animal Health, carrying a Zacks Rank #2 at present, has an earnings yield of 9.2% compared with the industry’s 2.8% yield. Shares of the company have climbed 43.1% against the industry’s 27.9% decline. PAHC’s earnings beat estimates in each of the trailing four quarters, the average surprise being 16.3%.